Arcturus Therapeutics (ARCT) Reports Q3 Loss of $0.49

Arcturus Therapeutics (NASDAQ: ARCT) reported Q3 EPS of ($0.49). Revenue for the quarter came in at $17.15 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• Apple has talked to PrismML about ways it could use its technology - The Information
• Benchmark Reiterates Hold Rating on Netflix (NFLX) Ahead of Q2 Results
• duPont REGISTRY Group files confidential IPO registration with SEC